Updated 2015-01-12 16:01. Published 2015-01-12 15:25
Company Description
Getinge
Getinge is one of the major medical companies on the Swedish stock exchange. The company works with solutions in the healthcare and life sciences …
& Gt; & gt;
. The business revolves around three brands: ArjoHuntleigh, GETINGE and MAQUET. Arjohuntleigh focus on patient management and patient hygiene, disinfection, DVT prevention, medical beds, therapeutic surfaces and diagnostics. Getinge provides solutions for infection control and prevention within healthcare and life sciences. MAQUET specializes in therapeutic applications, products, solutions and services for operating theaters and intensive care units. Headquartered in Halland Getinge.
Chairman
Carl Bennet
http: //www.getingegroup. com /
stock immediately fell on the news and had, at 15 o’clock declined by 3 percent to 169 crowns.
“There is no single factor that is decisive, but this is something that has emerged. I expressed this desire just before Christmas, but wanted to take responsibility for the challenges Getinge has with the US FDA. I wanted to give the board time to find a successor. Since then it has gone very quickly, “says Johan Malmquist.
Recent years Getinge has experienced difficulties as a result of claims by the FDA.
“We have been subject to the FDA’s attention. They have had comments on the quality management system within the Medical Systems business area. We have had a dialogue with them since the fall of 2013. We want to live up to their expectations and gain a greater understanding of what sanctions we can be coated with, “says Johan Malmquist.
New CEO for Getinge’s Alex Myers. He will assume his new position in connection with the AGM on 25 March 2015.
Alex Myers is is currently President and CEO of bed manufacturer Hilding Anders. Myers has a previous history of the Getinge Group as CEO of ARJOHUNTLEIGH and head of the Extended Care business area during the period from 2009 to 2013.
Johan Malmquist says to be proud that, during his time at the company have taken Getinge from “nothing to one of the world’s largest medical technology company 20-25.”
Even Getinge’s principal owner and Chairman Carl Bennet says he is very pleased with CEO Johan Malmquist’s work.
“Getinge valued at 5 billion when he took over as CEO. Today the company is valued at 40 billion. Then we had sales of 5-6 billion annually. Today we have a turnover five times as much, “says Carl Bennet, who is also chairman of Getinge’s Nomination Committee.
He says he even be in favor of electing Johan Malmquist on Getinge’s Board .
“It’s a thing of the Nominating Committee in 2016. But I like big main owner will obviously want to take advantage of the expertise. As everyone knows, I act in the long term when I appoint directors, “he says.
According to Carl Bennet However, there is no link between the change of CEO and Ghent Inge’s problems with the FDA.
“No there is there,” he says.
The share price falls Monday he sees as a natural response to “uncertainty” .
“Yes, that’s it always when it is a bit iffy. But we hope to sort it out when the FDA solution is in place around the end, “he says.
Gent Inge had previously hoped to present a solution to the FDA problem by the end of 2014 . Now say both Chairman Carl Bennet and CEO Johan Malmquist that a solution is expected to be completed around the end of January and February.
No comments:
Post a Comment